Targeting Toll-like receptors: emerging therapeutics? | Nature Reviews Drug Discovery
Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis - ScienceDirect
Is InDex Pharmaceuticals AB late reporting EU clinical trials?
JSB Market Research - PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
David T. Rubin, MD on Twitter: "Lots of options coming for #IBD (here showing pipeline for #UC). Need patients to participate in clinical trials! https://t.co/j70EPGoyyt" / Twitter
Sustained remission. (A) Proportion of placebo or cobitolimod treated... | Download Scientific Diagram
Kappaproct for Ulcerative Colitis Presentation Set for 2016 UEGW
UC Therapy Candidate Kappaproct Shows Potential with New Data
Ulcerative Colitis Therapy Kappaproct Focus of InDex Presentations at Digestive Disease Week
Pharmacological activity of DIMS0150. In the explorative phase IIa... | Download Scientific Diagram
Frontiers | Emerging Mechanisms of Innate Immunity and Their Translational Potential in Inflammatory Bowel Disease | Medicine
Symptomatic and clinical remission in patients with moderate, moderate... | Download Scientific Diagram
New Drug Pipeline Monitor, 7th Edition - December 2015
Kappaproct for Ulcerative Colitis Presentation Set for 2016 UEGW
Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets - Translational Research
As biosimilars advance in U.S., players jockey for position in IBD + | Bioworld | BioWorld
Company News: InDex Pharmaceuticals Develops Companion Diagnostic Test for New Ulcerative Colitis Therapy - akampion
EBSIN 04/2014 by BIOCOM AG - Issuu
Ulcerative Colitis IND Trial Application Cleared by FDA for InDex's Cobitolimod - IBD News Today
Symptomatic and clinical remission in patients with normal and elevated... | Download Scientific Diagram
IJMS | Free Full-Text | The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease | HTML
Pharmacy and Therapeutics December 2017 Contents View
Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis - Digestive and Liver Disease
Frontiers | Emerging Mechanisms of Innate Immunity and Their Translational Potential in Inflammatory Bowel Disease | Medicine
